Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AIM, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Rintatolimod | Chronic Fatigue Syndrome | Phase 3 · NCT00215800 | Completed |
| αDC1 Vaccine | Ovarian Cancer | Phase 2 · NCT07634094 | Not yet recruiting |
| Alferon LDO | HIV Infections | Phase 2 · NCT00215852 | Terminated |
| Recombinant Interferon Alfa-2b | Prostate Adenocarcinoma | Phase 2 · NCT03899987 | Active not recruiting |
| Trivalent Live-Attenuated Influenza Vaccine | Influenza, Human | Phase 1/2 · NCT01591473 | Terminated |
| Aspirin | Prostate Adenocarcinoma | Phase 2 · NCT03899987 | Active not recruiting |
| Creatine Kinase M-Type | Cancer of Ovary | Phase 1/2 · NCT02432378 | Withdrawn |
Also used in these trials (approved or third-party drugs, not AIM's own candidates): Pembrolizumab, Paclitaxel, Durvalumab, Cisplatin, Celecoxib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
AIM holds $6.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.8M/quarter from operations, an estimated runway of 5.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 80 · High
The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AIM files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Orca Capital AG | 5%+ holder (13G) | 1,793,999 | 4.49% | 2026-05-07 |
| Jane Street Group, LLC | Institution (13F) | 603,689 | 1.51% | 2026-09-30 |
| William M Mitchell Director |
Insider | 522,103 | 1.31% | 2025-04-21 |
| Peter W III Rodino COO, Secretary, Gen. Counsel · +100,000 options |
Insider | 401,762 | 1.01% | 2025-04-04 |
| Stewart Appelrouth Director |
Insider | 388,729 | 0.97% | 2024-12-31 |
| Thomas K Equels CEO & President, Director · +350,025 options |
Insider | 328,095 | 0.82% | 2026-11-11 |
| Nancy Bryan Director |
Insider | 291,882 | 0.73% | 2025-03-14 |
| Vanguard Fiduciary Trust Co | Institution (13F) | 241,835 | 0.61% | 2026-09-30 |
| UBS Group AG | Institution (13F) | 58,544 | 0.15% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 45,321 | 0.11% | 2026-09-30 |
| Ted D Kellner Director |
Insider | 37,205 | 0.09% | 2025-07-17 |
| Citigroup Inc. | Institution (13F) | 37,079 | 0.09% | 2026-09-30 |
Share count 39,919,844 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-11 filed 2026-11-13 |
Equels Thomas K |
Purchase (P) | 35,000 | $0.15 | 328,095 |
| 2026-11-10 filed 2026-11-12 |
Equels Thomas K |
Purchase (P) | 39,000 | $0.14 | 293,095 |
| 2026-11-09 filed 2026-11-10 |
Equels Thomas K |
Purchase (P) | 31,298 | $0.16 | 254,095 |
| 2026-11-06 filed 2026-11-09 |
Equels Thomas K |
Purchase (P) | 12,751 | $0.16 | 222,797 |
| 2026-10-23 filed 2026-10-26 |
Equels Thomas K |
Purchase (P) | 31,675 | $0.16 | 189,747 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AIM and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →